Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Impact of Pneumococcal Vaccination on Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1871.

https://doi.org/10.1182/blood.V130.Suppl_1.1871.1871

Published: 2017

Journal Articles

A New Model for Risk Stratification in Patients with Newly Diagnosed Multiple Myeloma: Impact of Serum Free Light Chains in Prognosis

José Luís García de Veas Silva, Johanna Carolina Rojas Novoa, Carmen Bermudo Guitarte, Stephen Harding, PhD, Luisa Campos, Rafael Duro Millan

Blood (2015) 126 (23): 5338.

https://doi.org/10.1182/blood.V126.23.5338.5338

Published: 2015

Journal Articles

Serum Free Light Chain Assays in the Risk Stratification of Monoclonal Gammopathy of Undetermined Significance: Results from a Pharmacoeconomic Evaluation

Guy Pratt, MDFRCP FRCPath, Holly Cranmer, BSc, Christine Almond, MSC, MMath, Stephen Harding, PhD, Dale John Powner, PhD, Richard Geir Hughes, DPhil, Mark Cook, PhD MBChb

Blood (2015) 126 (23): 3258.

https://doi.org/10.1182/blood.V126.23.3258.3258

Published: 2015

Journal Articles

Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques

Eileen M Boyle, MD, Julie Lejeune, Salomon Manier, MD, Lucile Musset, MD, Claire Bories, MD, Remy Dulery, Stéphanie Guidez, Sarah Bonnet, MD, Guillemette Fouquet, MD, Brigitte Onraed, MD, Jean-Luc Faucompré, MD, Sabine Tricot, MD, Stephanie Poulain, Veronique Leblond, MD PhD, Xavier Leleu, MD, Stephen Harding, PhD

Blood (2014) 124 (21): 2978.

https://doi.org/10.1182/blood.V124.21.2978.2978

Published: 2014

Journal Articles

Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma

Blood (2014) 124 (21): 3383.

https://doi.org/10.1182/blood.V124.21.3383.3383

Published: 2014

Journal Articles

Immunoglobulin Heavy/Light Chain Immunoassays for Response Evaluation in Multiple Myeloma: Comparison with Immunofixation, Serum Free Light Chain, and Multicolor Flow- Cytometry

Yasuhito Suehara, MD, Keisuke Seike, MD, Kouta Fukumoto, Manabu Fujisawa, MD, Masafumi Fukaya, MD, Hiroki Sugihara, MD, Masami Takeuchi, MD, Hiroyuki Takamatsu, MD PhD, Kelly Endean, Stephen Harding, PhD, Kosei Matsue, MD PhD

Blood (2014) 124 (21): 3366.

https://doi.org/10.1182/blood.V124.21.3366.3366

Published: 2014

Journal Articles

Immunoglobulin Heavy/Light Chain Measurements During Monitoring Provide Prognostic Information of Relapse After Therapy in Myeloma Patients

Mark T Drayson, MD, Oscar Berlanga, Tim Plant, Nicola J Newnham, Philip Young, Stephen Harding, PhD

Blood (2012) 120 (21): 3964.

https://doi.org/10.1182/blood.V120.21.3964.3964

Published: 2012

Journal Articles

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Josh Bornhorst, Adam Rosenthal, Rachael Sexton, Alan Mitchell, Linda Traylor, PhD, Antje Hoering, PhD, Frits van Rhee, MD, PhD, John Crowley, PhD, Nathan M Petty, Stephen Harding, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 3976.

https://doi.org/10.1182/blood.V120.21.3976.3976

Published: 2012

Journal Articles

The Ratio of Monoclonal to Polyclonal Immunoglobulins Assessed with the Hevylite Test Predicts Prognosis, Is Superior for Monitoring the Course of the Disease and Allows Detection of Monoclonal Immunoglobulin In Patients with Normal or Subnormal Involved Immunoglobulin Isotype

Heinz Ludwig, MD, Ladan Mirbahai, Niklas Zojer, PhD, MD, Arthur Bradwell, FRCP, FRCPath, Stephen Harding, PhD

Blood (2010) 116 (21): 4038.

https://doi.org/10.1182/blood.V116.21.4038.4038

Published: 2010

Journal Articles

Immunoglobulin Heavy/Light Chain Ratios as An Alternative to Immunofixation In the Identification of Monoclonal Gammopathies

Anandram Seetharam, Tracy Lovatt, Alan Macwhannell, Abe Jacob, MD, FRCP, FRCPath, Sunil Honda, Stephen Harding, PhD, Supratik Basu

Blood (2010) 116 (21): 5018.

https://doi.org/10.1182/blood.V116.21.5018.5018

Published: 2010

Journal Articles

Heavy Chain Ratio (HLCR) IgGκ/IgGλ or IgAκ/IgAλ: Experience and Clinical Implications In Multiple Myeloma at Diagnosis and During Disease Course

Efstathios Koulieris, Marie-Christine Kyrtsonis, Nikolitsa Kafassi, Dimitris Maltezas, Vassiliki Bartzis, Tatiana Tzenou, Maria Dimou, George Georgiou, Ladan Mirbahai, Panayiotis Panayiotidis, Arthur Bradwell, FRCP, FRCPath, Stephen Harding, PhD

Blood (2010) 116 (21): 5019.

https://doi.org/10.1182/blood.V116.21.5019.5019

Published: 2010

Journal Articles

Hevylite®, a New Marker of Tumor Measurement In Waldenstrom Macroglobulinemia

Salomon Manier, Remy Dulery, Alain Duhamel, Eileen Boyle, Julien Rossignol, Jean Luc Faucompret, Brigitte Onraed, Bernadette Hennache, Annie Pietrantuono, Frederic Combat, Stephanie Poulain, Irene M Ghobrial, MD, Véronique Leblond, Stephen Harding, PhD, Xavier Leleu, MD, PhD

Blood (2010) 116 (21): 5076.

https://doi.org/10.1182/blood.V116.21.5076.5076

Published: 2010

Journal Articles

Polyclonal Serum FLC Levels: a Simple Risk Stratification Model for Identifying Aggressive Stage A CLL.

Guy Pratt, Alison Levoguer, Jeffrey Faint, Chris Fegan, Chris Pepper, David Graham Oscier, MD, Anne Gardiner, Stephen Harding, PhD

Blood (2010) 116 (21): 4608.

https://doi.org/10.1182/blood.V116.21.4608.4608

Published: 2010

Journal Articles

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Helen J Lachmann, MD, FRCP, Stephen Harding, PhD, Ashutosh Wechalekar, MD, FRCPath, Julian D Gillmore, E. Nicole Amft, MD, PhD, FRCP, Philip N Hawkins

Blood (2010) 116 (21): 3958.

https://doi.org/10.1182/blood.V116.21.3958.3958

Published: 2010

Journal Articles

Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM

Attaya Suvannasankha, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Stephen Harding, PhD, Brian GM Durie, MD, Rafat Abonour, MD

Blood (2010) 116 (21): 2986.

https://doi.org/10.1182/blood.V116.21.2986.2986

Published: 2010

Journal Articles

Quantification of Serum IgMκ and IgMλ In Patients with Waldenstrom's Macroglobulinemia (WM) at Diagnosis and During Disease Course; Clinical Correlations

Efstathios Koulieris, Marie-Christine Kyrtsonis, Dimitris Maltezas, Tatiana Tzenou, Ladan Mirbahai, Nikolitsa Kafassi, Vassiliki Bartzis, Maria Dimou, George Georgiou, Charis Matsouka, Gerasimos Pangalis, Panayiotis Panayiotidis, Arthur Bradwell, FRCP, FRCPath, Stephen Harding, PhD

Blood (2010) 116 (21): 3004.

https://doi.org/10.1182/blood.V116.21.3004.3004

Published: 2010

Journal Articles

Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.

Herve AvetLoiseau, MD, Jean-Luc Harousseau, Philippe Moreau, MD, Claire Mathiot, Thierry Facon, Michel Attal, MD, Arthur Bradwell, FRCP, FRCPath, Stephen Harding, PhD

Blood (2009) 114 (22): 1818.

https://doi.org/10.1182/blood.V114.22.1818.1818

Published: 2009

Journal Articles

Analysis of the Serum Free Light Chain Ratio and Its Prognostic Value in a Cohort of Patients with Chronic Lymphocytic Leukemia.

Chaim Shustik, MD, Stephen Harding, PhD, Keyue Ding, Liting Zhu, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD, Lois Shepherd, MD, Melanie Robson

Blood (2009) 114 (22): 2631.

https://doi.org/10.1182/blood.V114.22.2631.2631

Published: 2009

Journal Articles

Serum FLC Levels at Presentation Have Independent Prognostic Significance in CLL and Levels Above 50mg/L Identify Patients with Progressive Disease.

Guy Pratt, Stephen Harding, PhD, Chris Fegan, Chris J Pepper, David Oscier, Anne Gardiner, Roger Holder, Arthur Bradwell, FRCP, FRCPath, Graham Mead, PhD

Blood (2009) 114 (22): 2355.

https://doi.org/10.1182/blood.V114.22.2355.2355

Published: 2009

Journal Articles

Abnormal Serum IgA Kappa / IgA Lambda Ratios at Maximum Response Predict Poor Progression Free Survival in Myeloma Patients.

Heinz Ludwig, MD, Stephen Harding, PhD, Caroline Bradley, Dejan Milosavljevich, Mark T Drayson, Gareth J Morgan, J. Anthony Child, Arthur Bradwell, FRCP, FRCPath

Blood (2009) 114 (22): 4879.

https://doi.org/10.1182/blood.V114.22.4879.4879

Published: 2009

NARROW

Impact of Pneumococcal Vaccination on Multiple Myeloma

A New Model for Risk Stratification in Patients with Newly Diagnosed Multiple Myeloma: Impact of Serum Free Light Chains in Prognosis

Serum Free Light Chain Assays in the Risk Stratification of Monoclonal Gammopathy of Undetermined Significance: Results from a Pharmacoeconomic Evaluation

Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques

Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma

Immunoglobulin Heavy/Light Chain Immunoassays for Response Evaluation in Multiple Myeloma: Comparison with Immunofixation, Serum Free Light Chain, and Multicolor Flow- Cytometry

Immunoglobulin Heavy/Light Chain Measurements During Monitoring Provide Prognostic Information of Relapse After Therapy in Myeloma Patients

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

The Ratio of Monoclonal to Polyclonal Immunoglobulins Assessed with the Hevylite Test Predicts Prognosis, Is Superior for Monitoring the Course of the Disease and Allows Detection of Monoclonal Immunoglobulin In Patients with Normal or Subnormal Involved Immunoglobulin Isotype

Immunoglobulin Heavy/Light Chain Ratios as An Alternative to Immunofixation In the Identification of Monoclonal Gammopathies

Heavy Chain Ratio (HLCR) IgGκ/IgGλ or IgAκ/IgAλ: Experience and Clinical Implications In Multiple Myeloma at Diagnosis and During Disease Course

Hevylite®, a New Marker of Tumor Measurement In Waldenstrom Macroglobulinemia

Polyclonal Serum FLC Levels: a Simple Risk Stratification Model for Identifying Aggressive Stage A CLL.

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM

Quantification of Serum IgMκ and IgMλ In Patients with Waldenstrom's Macroglobulinemia (WM) at Diagnosis and During Disease Course; Clinical Correlations

Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.

Analysis of the Serum Free Light Chain Ratio and Its Prognostic Value in a Cohort of Patients with Chronic Lymphocytic Leukemia.

Serum FLC Levels at Presentation Have Independent Prognostic Significance in CLL and Levels Above 50mg/L Identify Patients with Progressive Disease.

Abnormal Serum IgA Kappa / IgA Lambda Ratios at Maximum Response Predict Poor Progression Free Survival in Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only